GREY:ATBPF - Post by User
Comment by
Rayzzeron Mar 19, 2018 4:52pm
226 Views
Post# 27742437
RE:Another Possibility
RE:Another PossibilityAs per the NR on Oct 20, 2017:
Antibe will be meeting with several regional pharmaceutical companies to discuss potential out-licensing opportunities of ATB-346 in advance of clinical results from the on-going Phase 2b GI safety study – a data read-out remains on schedule for Q1 2018.
Dan Legault, Antibe’s CEO, remarked, “Securing additional regional licensing deals for ATB-346 will provide further validation of Antibe’s H2S technology and supports our goal of unlocking the most value for shareholders. In addition, this partnering activity provides an important source of non-dilutive funding for development of our pipeline of novel NSAIDs. With Phase 2b GI safety data only months away, we have been entering discussions with several parties who have expressed an interest in our lead drug, ATB-346.”
SizzlinSteaks wrote: Possibly an offer on the table pending positive results. Ya never know. I'm sure the pharmeceutical companies have been keeping a close eye on Antibe.